Skip to search formSkip to main contentSkip to account menu

S-CKD602

A sterically stabilized, pegylated liposomal formulation containing CKD602, a semi-synthetic analogue of campthotecin with potential antitumor… 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

Pegylated Liposomal Belotecan

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2014
2014
Immune mechanisms regulating pharmacokinetics and pharmacodynamics of PEGylated liposomal anticancer agents
2012
2012
Population Pharmacokinetics of Pegylated Liposomal CKD‐602 (S‐CKD602) in Patients With Advanced Malignancies
S‐CKD602 is a pegylated long‐circulating liposomal formulation of CKD‐602, a potent topoisomerase I inhibitor. A population… 
2012
2012
Mechanism-based model characterizing bidirectional interaction between PEGylated liposomal CKD-602 (S-CKD602) and monocytes in cancer patients
S-CKD602 is a PEGylated liposomal formulation of CKD-602, a potent topoisomerase I inhibitor. The objective of this study was to… 
2011
2011
Bidirectional pharmacodynamic interaction between pegylated liposomal CKD-602 (S-CKD602) and monocytes in patients with refractory solid tumors
Background: STEALTH® liposomal CKD-602 (S-CKD602), a camptothecin analog, is eliminated by the reticuloendothelial system (RES… 
2011
2011
Allometric scaling of pegylated liposomal anticancer drugs
Pegylated liposomal formulations contain lipid conjugated to polyethylene glycol. The disposition of encapsulated drug is… 
2011
2011
Tumor disposition of pegylated liposomal CKD-602 and the reticuloendothelial system in preclinical tumor models
Liposomes, such as pegylated-liposomal CKD-602 (S-CKD602), undergo catabolism by macrophages and dendritic cells (DCs) of the… 
2010
2010
Abstract 3700: Effect of gender on pharmacokinetic disposition of pegylated liposomal CKD-602 (S-CKD602) and optisomal topotecan (TLI) in rats
Proceedings: AACR 101st Annual Meeting 2010‐‐ Apr 17‐21, 2010; Washington, DC Introduction: S-CKD602 is a pegylated liposomal… 
2006
2006
Final results of a phase I and pharmacokinetic study of STEALTH liposomal CKD-602 (S-CKD602) in patients with advanced solid tumors.
2013 Background: S-CKD602 is a pegylated STEALTH liposomal formulation of CKD-602, a semi-synthetic analogue of camptothecin (CPT… 
2006
2006
Plasma, tissue and tumor disposition of STEALTH® liposomal CKD-602 (S-CKD602) and non-liposomal CKD-602, a camptothecin analogue, in mice bearing A375 human melanoma xenografts
3064 Introduction: S-CKD602 is a STEALTH® liposomal formulation of CKD-602, a camptothecin (CPT) analogue. The cytotoxicity of… 
2005
2005
Phase I and pharmacokinetic (PK) study of STEALTH liposomal CKD-602 (S-CKD602) in patients with advanced solid tumors
2069 Background: S-CKD602 is a pegylated STEALTH liposomal formulation of CKD-602, a semi-synthetic analogue of camptothecin… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)